» Articles » PMID: 38067212

The MYC-Regulated RNA-Binding Proteins HnRNPC and LARP1 Are Drivers of Multiple Myeloma Cell Growth and Disease Progression and Negatively Predict Patient Survival

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 9
PMID 38067212
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a malignant plasma cell disorder in which the MYC oncogene is frequently dysregulated. Due to its central role, MYC has been proposed as a drug target; however, the development of a clinically applicable molecule modulating MYC activity remains an unmet challenge. Consequently, an alternative is the development of therapeutic options targeting proteins located downstream of MYC. Therefore, we aimed to identify undescribed MYC-target proteins in MM cells using Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) and mass spectrometry. We revealed a cluster of proteins associated with the regulation of translation initiation. Herein, the RNA-binding proteins Heterogeneous Nuclear Ribonucleoprotein C (hnRNPC) and La Ribonucleoprotein 1 (LARP1) were predominantly downregulated upon MYC depletion. CRISPR-mediated knockout of either hnRNPC or LARP1 in conjunction with redundant LARP family proteins resulted in a proliferative disadvantage for MM cells. Moreover, high expression levels of these proteins correlate with high MYC expression and with poor survival and disease progression in MM patients. In conclusion, our study provides valuable insights into MYC's role in translation initiation by identifying hnRNPC and LARP1 as proliferation drivers of MM cells and as both predictive factors for survival and disease progression in MM patients.

Citing Articles

Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications.

Priya , Kumar A, Kumar D 3 Biotech. 2025; 15(1):33.

PMID: 39777154 PMC: 11700964. DOI: 10.1007/s13205-024-04195-0.

References
1.
Zeller K, Jegga A, Aronow B, ODonnell K, Dang C . An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003; 4(10):R69. PMC: 328458. DOI: 10.1186/gb-2003-4-10-r69. View

2.
Pourdehnad M, Truitt M, Siddiqi I, Ducker G, Shokat K, Ruggero D . Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013; 110(29):11988-93. PMC: 3718086. DOI: 10.1073/pnas.1310230110. View

3.
Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein M, Geiger T . The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016; 13(9):731-40. DOI: 10.1038/nmeth.3901. View

4.
Dang C, Reddy E, Shokat K, Soucek L . Drugging the 'undruggable' cancer targets. Nat Rev Cancer. 2017; 17(8):502-508. PMC: 5945194. DOI: 10.1038/nrc.2017.36. View

5.
Schmidt E . The role of c-myc in regulation of translation initiation. Oncogene. 2004; 23(18):3217-21. DOI: 10.1038/sj.onc.1207548. View